Aura Biosciences Stock

aurabiosciences.comHealthcare / BioTech & PharmaFounded: 2009Funding to Date: $225.08MM

Aura Biosciences is a biotechnology company developing a new class of therapies to target and destroy cancer cells selectively, while leaving surrounding tissue unharmed.

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to Aura Biosciences before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Company Sector IPO Date IPO Price/Share Price/Share as of 6/14/24 Since IPO
Aura Biosciences Healthcare 10/28/2021 $14 $7.33 -47.6%Forge negative stock iconForge positive stock icon
Round Date Series Amount Raised Post Money Valuation Price/Share Lead Investors Since IPO
3/21 E $80.4M $283.0M $0.78 Matrix Capital Management, Surveyor Capital, Rock Springs Capital, Adage Capital Management LP, Velosity Capital, Medicxi, Advent Life Sciences, Lundbeckfonden Ventures, Arix Bioscience, Chiesi Ventures, Ysios Capital, Columbus Venture Partners 839.7%Forge negative stock iconForge positive stock icon
7/20 D-2 $17.0M $157.2M $0.69 Undisclosed Investors 962.3%Forge negative stock iconForge positive stock icon
4/19 D-1 $39.9M $139.5M $0.69 Medicxi, Advent Life Sciences, Arix Biosciences, Chiesi Ventures, Columbus Venture Partners, Lundekfonden Ventures, Ysios Capital 962.3%Forge negative stock iconForge positive stock icon
12/17 C-2 $12.1M $73.0M $0.36 Lundbeckfonden Ventures, Arix Biosciences, Advent Life Sciences, Chiesi Ventures, Ysios Capital, Alexandria Venture Investments, Columbus Venture Partners, LI-COR Biosciences 1,936.1%Forge negative stock iconForge positive stock icon
12/17 C-1 $30.2M $73.0M $0.52 Lundbeckfonden Ventures, Arix Biosciences, Advent Life Sciences, Chiesi Ventures, Ysios Capital, Alexandria Venture Investments, Columbus Venture Partners, LI-COR Biosciences 1,309.6%Forge negative stock iconForge positive stock icon
3/15 B $28.2M $50.2M $1.24 Advent Life Sciences, Chiesi Ventures, Ysios Capital, Alexandria Venture Investments, LI-COR Biosciences 491.1%Forge negative stock iconForge positive stock icon
8/14 A-2 $5.3M $22.0M $1.24 Undisclosed Investors 491.1%Forge negative stock iconForge positive stock icon
7/13 A-1 $8.1M $29.1M $2.48 Undisclosed Investors 195.6%Forge negative stock iconForge positive stock icon
8/11 A $3.4M $16.0M $2.00 Undisclosed Investors 266.5%Forge negative stock iconForge positive stock icon
Primary round data: Forge Data. Current stock price: Quandl.
Past performance is no guarantee of future results. There can be no assurance that any investment will achieve its objectives or avoid substantial losses.

Frequently Asked Questions About Aura Biosciences’ Stock

plusminus
Can you buy Aura Biosciences’ stock?
You can no longer buy Aura Biosciences’ stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Aura Biosciences’ stock?
You can no longer sell stock of Aura Biosciences on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus
What is Aura Biosciences’ stock price?
The stock price of Aura Biosciences is $7.74 as of 1/18/24.
plusminus
What is Aura Biosciences’ stock ticker symbol?
The ticker symbol of Aura Biosciences is AURA.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Team

Management Team

Elisabet de los Pinos Ph.D
Co-Founder, Chief Executive Officer & Board Member
Denis O'Shaughnessy Ph.D
Head of Clinical Development
Richard Peters Ph.D
Advisor
Andrew Russell Ph.D
Director, Manufacturing
Stephen Monks Ph.D
Senior Vice President, Development
Alan Walts Ph.D
Executive Chairman
Julie Feder
Chief Financial Officer
Cadmus Rich MD
Chief Medical Officer
Michele Keough
Senior Vice President, R&D Operations

Board Members

Dale Pfost Ph.D
Advent Venture Partners
Elisabet de los Pinos Ph.D
Casper Breum
Lundbeckfonden
Henri Termeer
Javier García
Columbus Venture Partners
Rajesh Parekh Ph.D
Advent Life Sciences
Arthur Pappas
Chiesi Ventures
Giovanni Mariggi Ph.D
Medicxi
Joël Jean-Mairet Ph.D
Ysios Capital
Salvador Garcia-Atance Ph.D
Israel Ruiz
Alan Walts Ph.D
Mark Chin
Arix Bioscience

News

Aura Biosciences Appoints George Golumbeski, Ph.D., as Chairman of the Board of Directors
Aura Biosciences, a clinical-stage biopharmaceutical company developing a new class of tumor targeted therapies for initial application in primary tum
Updated on: Jun 15, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.